Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
complement-mediated diseases
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "complement-mediated diseases" in MCE Product Catalog:
13
Target:
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
13
13 Publications Verification
別名: LNP023 hydrochloride
Target:
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
1
1 Cited Publications
製品番号: HY-P3252A
Target:
研究分野:
製品番号: HY-P99965
CAS 番号: 1917321-26-6
別名: SKY59; RO7112689; RG-6107
Target:
製品番号: HY-NP004
別名: CVF
製品番号: HY-P99050
CAS 番号: 2049079-64-1
別名: BIVV009; IPN-009; TNT009
Target:
研究分野:
製品番号: HY-P990091
CAS 番号: 2756228-76-7
別名: SAR 445088
製品番号: HY-145720
CAS 番号: 1639264-46-2
別名: ALN-CC5
研究分野:
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
製品番号: HY-P99786
CAS 番号: 2096328-94-6
別名: REGN3918
Target:
研究分野:
製品番号: HY-145720A
純度: 96.02%
別名: ALN-CC5 sodium
Cemdisiran sodium (ALN-CC5 sodium) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran sodium targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran sodium exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran sodium achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran sodium can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
製品番号: HY-P991513
Target:
研究分野:
製品番号: HY-200854
CAS 番号: 2447007-60-3
別名: LNP023 hydrochloride hydrate
Target:
Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
製品番号: HY-178284
Target:
研究分野:
Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases .
製品番号: HY-P990649
CAS 番号: 1169717-01-4
別名: TRU-015
Target:
研究分野:
製品番号: HY-127105B
CAS 番号: 1644670-38-1
別名: LNP023 TFA
Target:
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
製品番号: HY-P3252AS
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
